Activation of endothelial cells by IL-1b triggers the expression of multiple inflammatory cytokines and leukocyte-attracting chemokines. The machineries involved in the secretion of these inducible proteins are poorly understood. With the use of genome-wide transcriptional analysis of inflamed human dermal microvascular endothelial cells, we identified several IL-1b2 induced candidate regulators of these machineries and chose to focus our study on TNF-a-induced protein 2 (myeloid-secretory). The silencing of myeloidsecretory did not affect the ability of inflamed endothelial cells to support the adhesion and crawling of effector T lymphocytes. However, the ability of these lymphocytes to complete transendothelial migration across myeloid-secretory-silenced human dermal microvascular endothelial cells was inhibited significantly. These observed effects on lymphocyte transendothelial migration were recovered completely when exogenous promigratory chemokine CXCL12 was overlaid on the endothelial barrier. A polarized secretion assay suggested that the silencing of endothelial myeloid-secretory impairs T effector transendothelial migration by reducing the preferential secretion of endothelial-produced CCL2, a key transendothelial migration-promoting chemokine for these lymphocytes, into the basolateral endothelial compartment. Myeloidsecretory silencing also impaired the preferential secretion of other endothelial-produced inflammatory chemokines, as well as cytokines, such as IL-6 and GM-CSF, into the basolateral endothelial compartment. This is the first evidence of a novel inflammation-inducible machinery that regulates polarized secretion of endothelial CCL2 and other inflammatory chemokines and cytokines into basolateral endothelial compartments and facilitates the ability of endothelial CCL2 to promote T cell transendothelial migration.
Introduction
Activation of ECs by primary inflammatory cytokines, such as IL-1b and TNF, initiates gene expression of multiple leukocyte trafficking molecules, such as adhesion molecules and chemotactic cytokines that promote leukocyte TEM [1] . The process of leukocyte TEM was reconstituted successfully by many labs that use various in vitro cytokine-stimulated endothelial monolayers and real-time videomicroscopy readouts under physiologic shear flow [2] [3] [4] . Microvascular ECs are a prototype model for the investigation of adhesive and chemotactic mechanisms used by inflamed blood vessels to recruit multiple types of effector leukocytes to sites of inflammation [5] . Previously, we have shown that TEM of lymphocytes across these and other cytokineactivated EC monolayers is tightly regulated by chemokine signals [6] . These and other studies suggested that lymphocyteendothelial interactions are controlled by 2 modalities of chemokine presentation, namely, extracellular (derived from both endothelial and subendothelial secreted depots) [7, 8] , and intraendothelial chemokine depots (in the form of vesicle-stored pools of endothelial-produced inflammatory chemokines) [6] . Whereas most naïve and memory T cells may rely on the first modality of chemokine presentation, effector T cells are a unique subset of lymphocytes that are capable of using this second modality as a result of their ability to interact avidly with inflamed ECs in the absence of extracellular chemokine depots [6] .
In the present work, we aimed to identify novel factors that regulate the TEM-promoting activities of ECs. With the use of genome-wide expression profiling of IL-1b-stimulated HDMVECs, we identified TNFAIP2 (M-sec) as a possible TEMpromoting factor and as a regulator of endothelial cytokine secretion. M-sec was first identified as TNFAIP2 in HUVECs [9] and was also found to be induced in LPS-stimulated dendritic cells [10] , yet its proinflammatory functions in these different cell type remain unknown. In light of its homology to the exocyst component EXOC3 [11] , we speculated that this protein could be involved in the exocytosis of endothelial-produced inflammatory chemokines and therefore, in the ability of these chemokines to promote the migration of effector T cells across inflamed ECs. The silencing of M-sec expression in inflamed HDMVECs indeed impaired T cell TEM promoted by endothelial CCL2, a key monocyte and T cell TEM-promoting chemokine [2, 6] . Importantly, M-sec silencing did not affect initial steps of this multistep process preceding TEM, such as T cell rolling, arrest, adhesion strengthening, and crawling on inflamed HDMVECs. We also provide evidence that M-sec interacts with motor proteins and is required for the preferential secretion of CCL2 and of other endothelial cytokines into the basolateral compartments of inflamed HDMVECs. Our results support a novel role for M-sec in regulating polarized secretion of endothelial-produced cytokines. This work provides a first link between optimal lymphocyte TEM and polarized secretion of endothelial-produced chemokines into the basolateral endothelial compartment.
MATERIALS AND METHODS

Cells and reagents
HDMVECs (C-12211; PromoCell, Heidelberg, Germany) were grown in PromoCell EC medium MV (C-22020), according to the supplier's instructions, and were used at Passages 2-3. All in vitro experiments with human leukocytes were approved by the Institutional Review Board of the Rambam Medical Center, in accordance with the provisions of the Declaration of Helsinki. Human T cells were isolated, as described previously [6] . Peripheral blood T cells were used for the production of effector lymphocytes by seeding on plates coated with anti-CD3 (OKT3; BioLegend, San Diego, CA, USA) and anti-CD28 (CD28.2; BioLegend) and cultured for 9-12 d with IL-2, as described previously [12] . Before experiments, effector lymphocytes were washed and kept overnight in fresh IL-2-containing medium. The CCR2 blocker, BMS CCR2 22 (Cat. 3129; Tocris, Minneapolis, MN, USA), was used at 1 mM, as described [6] .
Transcriptome analysis of HDMVECs RNA extraction. For RNA extraction, cells were harvested in QIAzol lysis solution (Qiagen, Venlo, Netherlands), and total RNA was extracted using the miRNeasy Mini Kit (Qiagen). RNA quantity was determined by a NanoDrop spectrophotometer.
RNA-seq. RNA-seq libraries were prepared, as described previously [13] . Poly A RNA was fragmented into an average size of 300 nucleotides by incubation of the RNA in 95°C for 4½ min in fragmentation buffer (NEBNext Magnesium RNA Fragmentation Module; New England BioLabs, Ipswich, MA, USA). The 39 polyadenylated fragments were enriched by selection on poly (deoxythymidylic) beads (Dynabeads; Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA). Strand-specific cDNA was synthesized using a poly T-VN oligo (18 T) and AffinityScript RT enzyme (Agilent, Santa Clara, CA, USA).
dsDNA was obtained using a second-strand synthesis kit (NEBNext mRNA Second Strand Synthesis Module; New England BioLabs). DNA was purified by adding paramagnetic SPRI beads (Agencourt AMPure XP; Beckman Coulter, Brea, CA, USA). Supernatant were separated from the beads using a 96-well magnet. Beads were washed on the magnet with 70% ethanol and then air dried. The DNA was eluted in elution buffer (10 mM Tris-HCl, pH 8.0). For the remainder of the library construction process (DNA end-repair, A-base addition, adaptor ligation and enrichment), a general SPRI cleanup involves addition of buffer containing 20% polyethylene glycol and 2.5 M NaCl to the DNA reaction. DNA ends were first repaired by T4 polymerase (NEBNext; New England BioLabs), followed by the addition of a phosphate group at the 59 ends by T4 polynucleotide kinase (New England BioLabs). An adenosine base was then added to the blunt-ended fragments using Klenow enzyme (New England BioLabs), and a barcode Illumina compatible adaptor (Integrated DNA Technologies, Coralville, IA, USA) was ligated to each fragment using T4 quick ligase (New England BioLabs). DNA fragments were amplified by 12 cycles of PCR (KAPA HiFi HotStart ReadyMix; Kapa Biosystems, Wilmington, MA, USA) using specific primers (Integrated DNA Technologies) to the ligated adaptors. Library quantity was determined by Qubit Fluorometric Quantitation (Life Technologies, Carlsbad, CA, USA), and the quality of each library was analyzed by TapeStation (Agilent).
Preprocessing of RNA-seq. An average of 4 million reads was sequenced per library. All reads were aligned to the human reference genome (hg19) using the TopHat aligner [14] with default parameters. For detailed information, refer to Bornstein et al. [13] .
Gene-expression analysis. GENE-E (http://www.broadinstitute.org/cancer/software/GENE-E/index.html) was used to cluster the variant genes according to K-means of 10, 1 2 Pearson correlation.
qPCR
Total RNA was reverse transcribed into cDNA using a high-capacity cDNA reverse transcription kit (Applied Biosystems, Waltham, MA, USA). qPCR was performed with LightCycler480 SYBR Green I Master Mix (Roche, Basel, Switzerland) in triplicate, with GAPDH used as an endogenous control for normalization.
Generation of lentiviral vectors and gene transduction
Lentiviral particles were generated, as described previously [15] . In brief, Lipofectamine 2000 (Invitrogen, Thermo Fisher Scientific) was used to transfect 293T human embryonic kidney cells with the packaging plasmids pLP1, pLP/VSVG and pLP2, together with the pLKO.1 vector encoding M-sec shRNA (targeting sequence: CCGGAGGCAAGCAGCTGACGAATTACTC-GAGATAATTCGTCAGCTGCTTGCCTTTTTT) or nonmammalian shRNA control (targeting sequence: CCGGCAACAAGATGAAGAGCACCAACTC-GAGTTGGTGCTCTTCATCTTGTTGTTTTT; Sigma, St. Louis, MO, USA). Supernatants containing lentiviral particles were collected 48 h after transfection and were used to transduce HDMVECs. Silenced HDMVECs were selected usig puromycin (2 mg/ml for 48 h), 24 h after transduction.
Analysis of T cell migration under shear flow
Unless otherwise indicated, primary HDMVECs were plated at confluence on plastic-or glass-bottom dishes, spotted with 2 mg/ml fibronectin (Cat. #F0895; Sigma), and were stimulated for 3 or 12 h with IL-1b (2 ng/ml), as described previously [16] . The EC-containing plates were assembled in the flow chamber and washed extensively; T cells were perfused over the EC monolayers in binding medium (HBSS containing 2 mg/ml BSA and 10 mM HEPES, pH 7. Fluorescence and EM of fixed samples Samples were fixed with PBS containing 4% (wt/vol) paraformaldehyde and 2% (wt/vol) sucrose. For intracellular immunostaining, fixed cells were permeabilized with saponin (0.1%, 5 min), washed, blocked with 10% (vol/vol) goat serum, and incubated with primary fluorescence-labeled mAb or unlabeled mAb, followed by secondary antibody or with the nuclear dye Hoechst 33342. The DeltaVision system was used for fluorescence microscopy. Images were obtained with a Plan Apo objective (603 oil-immersion objective). Sections were acquired as serial z-stacks (0.2 mm) and were subjected to digital deconvolution (softWoRx; Applied Precision, GE Healthcare). For EM, cells were fixed and processed, as described previously [16] .
Polarized secretion of endothelial-expressed cytokines and chemokines
For polarized secretion assays, HDMVECs were grown on 24 mm Transwell inserts having 3 mm pores (Cat. #3414; Costar, Corning, NY, USA). Transwell filters were coated with 2 mg/ml fibronectin (Sigma) for 1 h and washed with PBS, and HDMVECs were seeded. Sixteen hours later, cells were stimulated using 2 ng/ml IL-1b for 3 h, washed twice, and incubated with serum-free media containing 0.2% Fraction V human serum albumin (Cat. #12666; Calbiochem, EMD Millipore, Billerica, MA, USA) for an additional 1 h. Supernatants from upper and lower reservoirs were collected. Cytokine and chemokine concentrations were analyzed by standard (for CCL2) or multiplex ELISA. After supernatant collection, the integrity of the EC monolayer on the Transwell filters was validated by measuring the ability of the monolayer to sustain a gradient of FITC-Dextran (Cat. #46945; Sigma) for 1 h. The gradient was generated by introduction of a 33 and 13 solution of the fluorescence Dextran to the upper and lower Transwell compartments, respectively.
ELISA
HDMVECs were stimulated using 2 ng/ml IL-1b for the indicated times before they were washed twice in serum-free media and incubated in serum-free media for an additional 1 h. Human CCL2 levels in media were determined by ELISA using standard curves with recombinant human CCL2 (Cat. #300-04; PeproTech, Rocky Hill, NJ, USA) at the linear range of absorbance. The following antibodies were used (all from PeproTech): coating mouse mAb (Cat. #500-M71) and detecting biotinylated rabbit polyclonal antibodies (Cat. #500-P34Bt). After the addition of streptavidin-HRP (Cat. #016-030-084; Jackson ImmunoResearch Laboratories, West Grove, PA, USA), the substrate tetramethylbenzidine/ELISA solution (Cat. #ES001; EMD Millipore) was added. The reaction was stopped by the addition of 0.18 M H 2 SO 4 , and the absorption was measured at 450 nm.
Multiplex ELISA
Multiplex ELISA was performed using the Magnetic Luminex Screening Assay Kit (R&D Systems, Minneapolis, MN, USA), according to the instructions of the manufacturer. Samples were read using a Magpix instrument (Bio-Rad Laboratories, Hercules, CA, USA).
Coimmunoprecipitation
HDMVECs, grown on 3, 150 mm tissue-culture plates, were stimulated with IL-1b for 12 h, trypsinized, washed twice in cold PBS, and lysed in 0.5 ml lysis buffer (10% glycerol, 0.1% NP-40, 2 mM EDTA, 1 mM NaF, 2 mM Na 3 VO 4 in PBS). Lysate was centrifuged for 10 min at 13,000 g, and supernatant was split to 2 new tubes and incubated with Dynabeads Protein G (Cat. #10003D; Thermo Fisher Scientific), conjugated to mouse anti-M-sec (sc-48418; Santa Cruz Biotechnology, Santa Cruz, CA, USA) or to mouse IgG 1 isotype control (clone MG1-45, Cat. #401401; BioLegend) at 4°C for 6 h with constant agitation. Beads were recovered and washed twice in PBS containing 0.05% NP-40. Elution was done using 150 ml 0.1 M glycine, pH 2.5, for 5 min at room temperature. Elution was analyzed by LC-MS/MS.
MS proteomics (LC-MS/MS)
Sample preparation. Protein concentration from each sample was determined using a bicinchoninic acid assay. Samples were subjected to insolution tryptic digestion. Proteins were first reduced by incubation with DTT (5 mM; Sigma) for 30 min at 60°C and alkylated with 10 mM iodoacetamide (Sigma) in the dark for 30 min at 21°C. Proteins were then subjected to digestion with trypsin (Promega, Madison, WI, USA) at a 1:50 trypsin:protein ratio for 16 h at 37°C. The digestions were stopped by trifluroacetic acid (1%). Peptides were desalted using solid-phase extraction columns (Oasis hydrophilic-lipophilic balance; Waters, Milford, MA, USA). The samples were stored in 280°C until further analysis.
LC. Ultrahigh LC/MS-grade solvents were used for all chromatographic steps. Each sample was loaded using split-less Nano UPLC (10 kpsi nanoAcquity; Waters). The mobile phase was: 1) H 2 O + 0.1% formic acid and 2) acetonitrile + 0.1% formic acid. Desalting of the samples was performed online using a reverse-phase C18 trapping column (180 mm internal diameter, 20 mm length, 5 mm particle size; Waters). The peptides were then separated using a T3 hollow structural section nano-column (75 mm internal diameter, 250 mm length, 1.8 mm particle size; Waters) at 0.35 ml/min. Peptides were eluted from the column into the mass spectrometer using the following gradient: 4-35% acetonitrile solution in 105 min, 35-90% acetonitrile solution in 5 min, maintained at 95% for 5 min, and then back to initial conditions.
MS. The Nano-UPLC was coupled online through a nano-electrospray ionization emitter (10 mm tip; New Objective, Woburn, MA, USA) to a quadrupole Orbitrap mass spectrometer (Q Exactive Plus; Thermo Fisher Scientific) using a Nanospray Flex ion apparatus (Thermo Fisher Scientific). Data were acquired in data-dependent acquisition mode using a Top12 method. MS1 resolution was set to 60,000 (at 400 mass-to-charge ratio) and maximum injection time was set to 120 ms. MS2 resolution was set to 17,500 and a maximum injection time of 60 ms.
Data processing and analysis. Raw data were imported into the Expressionist software (Genedata, Basel, Switzerland) and processed as described [17] . The software was used for retention-time alignment and peak detection of precursor peptides. A master peak list was generated from all MS/MS events and sent for database searching using Mascot v2.5 (Matrix Science, Boston, MA, USA). Data were searched against the human sequences in UniProtKB/Swiss-Prot database version 2014_04 (http://www.uniprot.org/), appended with 125 common laboratory contaminant proteins. Fixed modification was set to carbamidomethylation of cysteines, and variable modification was set to oxidation of methionines. Peptide identifications were imported back to Expressionist to annotate identified peaks. Search results were then filtered to achieve a maximum false discovery rate of 1% at the protein level. Quantification of proteins from the peptide data was performed using an in-house script [17] .
RESULTS
EC transcriptome analysis and identification of TEM-promoting gene candidates
Stimulation of ECs by inflammatory cytokines, such as IL-1b or TNF, initiates a proinflammatory genetic program that is mediated primarily by NF-kB and is known as type II endothelial activation. This activation enables ECs to recruit leukocytes to sites of inflammation through de novo expression of adhesion molecules and chemotactic cytokines [1] . Indeed, short HDMVEC stimulation with IL-1b allowed these cells to support robust adhesion and TEM of effector T cells (Fig. 1A and B) .
Although considered proinflammatory in some settings [18, 19] , VEGF-A, which does not activate NF-kB, failed to trigger any lymphocyte adhesion or TEM (Fig. 1B) . The different promigratory phenotypes of these stimulations allowed us to identify novel endothelial factors that contribute to leukocyte TEM by comparing the genome-wide expression of IL-1b-with VEGF-A-stimulated HDMVECs. To that end, we analyzed the expression levels of 5028 genes across the time course of IL-1b or VEGF-A stimulation ( Fig. 2A and Supplemental Table 1 ). We first examined the transcription profiles of known TEM-promoting vascular adhesion molecules and chemotactic factors and found them as follows: 1) to be more responsive to IL-1b than to VEGF-A and 2) to increase dramatically within the first 2 h after stimulation (Fig. 2B ). Based on these 2 criteria, we searched for additional genes, potentially involved in lymphocyte TEM, and identified 30 genes that met these criteria (Fig. 2B ). This group included gene-encoding factors with known inflammatory functions, such as inflammatory cytokines, transcription factors, and NF-kB regulators, as well as genes without a known function in inflammation or in leukocyte TEM [20] . We chose to focus on TNFAIP2 (M-sec), as its absolute transcript levels were highly abundant following IL-1b stimulation, and it was annotated as a vesicle transport factor [20] . As effector T cells use chemokine vesicles for their TEM across IL-1b-inflamed ECs, we postulated that M-sec could be involved in the transport and function of the TEM-promoting chemokines expressed by our modelinflamed ECs.
M-sec localizes to the plasma membrane and nuclei of inflamed ECs, but its silencing does not affect IL-1b-triggered gene transcription As our effector lymphocyte TEM studies are performed routinely with ECs, stimulated for 3 or 12 h [15] , we next analyzed M-sec protein levels and intracellular distribution at these representative time points. At both time points, M-sec was localized primarily inside the nucleus and at cell junctions (Fig. 3A) . This distribution pattern was in line with the high sequence homology of M-sec to EXOC3, an exocyst component also found in nuclear and cytosolic compartments in HeLa cells [21] .
The nuclear localization of M-sec could suggest a transcription regulatory role for this factor. Therefore, we next explored whether M-sec silencing affects IL-1b-induced gene expression, in particular, of known targets of NF-kB activation, such as adhesion molecules and inflammatory chemokines. Ectopic expression of shRNA, selectively targeting M-sec, resulted in complete silencing of the protein expression at early and late time points of IL-1b stimulation (Fig. 3B) . Nevertheless, the transcription levels of ICAM-1, VCAM-1, and E-selectin, as well as of all major IL-1b-induced endothelial chemokines, were unaffected by M-sec silencing (Fig. 3C) . Protein expression levels and distribution of ICAM-1 and E-selectin within inflamed HDMVECs were also not affected by M-sec silencing (data not shown). Furthermore, production and deposition by these cells into the basement membrane of the extracellular matrix proteoglycan perlecan, a marker of endothelial polarity [22] , were also M-sec independent (data not shown). Notably, all other IL-1b-induced endothelial transcripts were also unaffected by this silencing, as confirmed by genome-wide transcriptional analysis (Supplemental Table 2 ). These results strongly suggest that M-sec is not necessary for normal transcription of endothelial genes induced by IL-1b and rules out a putative role of this factor as a transcription regulator in IL-1b-inflamed ECs.
Lymphocyte TEM, promoted by endogenous endothelial chemokines, is partially inhibited by silencing endothelial M-sec expression
To elucidate further the potential function of M-sec in endothelial inflammation, we next determined the adhesive and promigratory capacities of sham-treated or M-sec-silenced HDMVECs activated by IL-1b. In agreement with the normal transcription of E-selectin, ICAM-1, and VCAM-1, the ability of these cells to support effector T cell accumulation and resistance to detachment by continuously applied shear forces was unchanged by M-sec silencing ( Fig. 4A ; detachment and arrest categories). However, M-sec silencing resulted in a moderate but significant reduction in the ability of IL-1b-inflamed HDMVECs to promote effector T cell TEM ( Fig. 4A ; TEM category, P , 0.001). This inhibition of TEM was mirrored by an increase in the portion of effector T lymphocytes that continued to crawl over the endothelial monolayer without subsequent transmigration ( Fig. 4A ; crawling category, P , 0.001). Whereas the time required for originally arrested effector T cells to reach potential exit sites at endothelial junctions was not prolonged by M-sec silencing (Supplemental Fig. 1 ), kinetic analysis of the migration revealed that M-sec silencing led to a delay in initial lymphocyte TEM (Fig. 4B) . Notably, the reduction and the delay in T cell TEM remained significant even under prolonged IL-1b stimulation of HDMVECs, which resulted in near-saturating levels of T cell TEM across sham-treated ECs (Fig. 4C and D) .
We have shown previously that optimal TEM of effector T cells across inflamed ECs requires a proper response to endothelialproduced inflammatory chemokines [6, 15] . Nevertheless, successful leukocyte TEM requires additional endothelial machineries not related to chemokine activities [23] . To examine the potential involvement of endothelial M-sec in these different processes, we next asked whether introduction of an exogenous promigratory chemokine to an endothelial monolayer, blocked in the ability of its endogenous chemokines to promote T cell TEM, would rescue the inhibitory effect of endothelial M-sec silencing. Short pretreatment of IL-1b-stimulated HDMVECs with BFA, a toxin that strongly interferes with the TEMpromoting activity of endogenous endothelial chemokines by depleting their storage in vesicles [6] , completely disrupted the ability of IL-1b-stimulated HDMVECs to promote effector T cell TEM (Fig. 4E, left bars) . Nevertheless, when these BFApretreated, IL-1b-stimulated HDMVECs were overlaid with exogenous CXCL12-a potent promigratory chemokine [24, 25] -a strong T cell TEM was observed, and both effects of M-sec silencing on the extent and kinetics of TEM were rescued completely (Fig. 4E, middle and right bars, and F) . These results collectively suggest that endothelial M-sec contributes to effector lymphocyte TEM by affecting their encounter of endogenous endothelial chemokines rather than by controlling other chemokine-independent endothelial-remodeling machineries critical for optimal lymphocyte crossing.
We have shown previously that T cell TEM strongly correlates with the ability of crawling T cells to send invasive protrusions into the ECs that they cross in response to endothelial-produced chemokines [6, 16] . To dissect the possible involvement of endothelial M-sec in this protruding step, we next compared the number of protrusions sent by effector T cells into the EC that they crawl on using scanning EM imaging. Surprisingly, no differences were detected in the average number of protrusions sent by crawling T cells into sham-or M-sec-silenced ECs (Fig. 5A  and B) . Together with the adhesion and migration results presented in Fig. 4 , this suggested that M-sec is not required for the ability of effector T cells to crawl and send invasive protrusions into inflamed ECs. Collectively, this analysis suggested that endothelial M-sec is necessary for successful completion of T cell TEM but not for earlier phases of this process (Fig. 5C ).
M-sec is required for polarized secretion of CCL2 into the basolateral compartment of inflamed ECs
Thus far, our data suggested that M-sec regulates the proper encounter of endogenous endothelial chemokines by effector T cells transmigrating through inflamed HDMVECs. We have shown previously that CCL2 is the major endothelial-produced inflammatory chemokine involved in effector T cell TEM across TNF-inflamed ECs [6] . Therefore, we validated that CCL2 is the most abundant CCR2 ligand expressed by IL-1b-activated HDMVECs (Supplemental Table 1 ) and that CCR2 on effector T cells is the predominant chemokine receptor implicated in the TEM of these lymphocytes across IL-1b-stimulated HDMVECs (Fig. 6A) . Furthermore, we also validated that this inflamed endothelial model expresses negligible levels of alternative inflammatory chemokine ligands to other G-protein-coupled receptors, expressed by T effector cells, such as CXCL10, CCL5, CCL21, and CXCL12 (Supplemental Table 1 ). These data collectively indicated that CCL2, produced by IL-1b-activated HDMVECs, is the key inflammatory chemokine that promotes effector T cell TEM across these inflamed ECs. Next, we tested whether M-sec silencing affects CCL2 expression, intracellular distribution, and secretion from IL-1b-inflamed HDMVECs. The levels of intraendothelial CCL2 and its distribution in endothelial vesicles were not altered by M-sec silencing (Fig. 6B) . Furthermore, the total amount of CCL2 secreted from resting or inflamed confluent HDMVECs, grown on a filter and allowed to polarize similarly (Supplemental Fig. 2) , was unaffected by M-sec silencing (Fig. 6C) . However, whereas IL-1b-inflamed HDMVECs secreted, on average, 40% more CCL2 into their basolateral compartment than into the apical compartment, M-sec-silenced HDMVECs secreted essentially equal amounts of CCL2 into both compartments (Fig. 6D) . Nevertheless, M-sec-silenced and shamtreated HDMVEC monolayers sustained an exogenous FITC-Dextran gradient, indicating low and similar monolayer permeability indexes for both endothelial monolayers (Fig. 6E) . This result implicates M-sec in the secretion of endothelial-produced CCL2 into the basolateral aspects of inflamed HDMVECs.
M-sec contributes to polarized secretion of other inflammatory cytokines from inflamed dermal ECs
We next wished to test the potential role of M-sec in the secretion patterns of other inflammatory cytokines produced by IL-1b-stimulated HDMVECs. Therefore, we quantified the secretion levels of 3 additional inflammatory chemokines (CXCL1, CXCL8, and CCL20) and 2 inflammatory cytokines (IL-6 and GM-CSF), produced by HDMVECs in response to IL-1b stimulation. As observed with CCL2, M-sec silencing did not affect the total secreted amounts of the tested chemokines or cytokines ( Fig. 7A and B) . Four of the 5 tested inflammatory chemokines and cytokines were secreted preferentially into the basolateral aspect of IL-1b-stimulated HDMVECs, with the exception of CCL20, which was evenly secreted to apical and basolateral compartments (Fig. 7C and D) . Furthermore, similar to our observations of a preferential CCL2 secretion, M-sec silencing impaired the polarized secretion of all 4 chemokines and cytokines exhibiting this secretion pattern (Fig. 7C and D) . Although a role for M-sec in T cell TEM was also observed, 12 h after IL-1b stimulation, we did not detect polarized cytokine secretion at this time point, as prolonged endothelial stimulation by IL-1b resulted in a complete mixing between the apical and basolateral compartments (data not shown). Collectively, this is a first demonstration that IL-1b-inflamed ECs secrete multiple inflammatory cytokines, preferentially into the basolateral endothelial compartments, and that M-sec contributes to this polarized cargo secretion.
The interactome of endothelial M-sec is enriched with actin-associated proteins
To gain a better understanding of how M-sec mediates its effect on polarized cargo secretion, we next performed coimmunoprecipitation of endogenous M-sec in lysates of IL-1b-stimulated HDMVECs, followed by LC-MS/MS analysis. This unbiased method enabled us to detect specific partners of M-sec, potentially involved in its novel function. To eliminate falsepositive hits, we excluded prevalent contaminants, such as keratins, ribosomal proteins, and serum components. The 40 most abundant proteins, identified with at least 2 unique peptides, are reported in Supplemental Table 3 , all of which had protein confidence $99% and .100-fold intensity over the isotype control sample. The Unified Human Interactome [26] was queried to construct a potential interaction network (Fig. 8) .
Many of the M-sec-associated proteins were reported to interact with each other, enabling us to cluster them into functional groups. The group of actin-associated proteins stood out with .½ of the identified proteins (23 out of 40). Indeed, the Panther overrepresentation test [27] indicates significant enrichment of "actin family cytoskeletal proteins" (P = 8.8 3 10 219 ) and of "actin-binding motor proteins" (P = 4.7 3 10
29
). These 2 groups included several effectors known to control vesicular trafficking and exocytosis, such as myosin 1c, tropomyosins 1-4, and tropomodulin 3 [28] [29] [30] [31] [32] [33] . Importantly, M-sec interaction with myosin 1c was confirmed by immunostaining (Supplemental Fig.  3 ). In addition to these exocytosis-related factors, the vesicular protein clathrin was found to interact with M-sec. These results 
DISCUSSION
ECs control lymphocyte TEM by different machineries that promote different steps of leukocyte adhesion and sensing of chemotactic exit signals [34] . In an effort to gain a deeper understanding of this multifactorial process, we analyzed the proinflammatory transcriptome induced by IL-1b, a cytokine shown by us [6] and others to promote robust leukocyte TEM [3, 35] , and compared it with the transcriptome induced by VEGF-A, an EC growth factor that fails to promote leukocyte TEM. According to the transcription patterns of known TEMpromoting factors, we established a transcription profile of TEMpromoting factors and thereby, identified novel genes potentially involved in TEM of T cells. Among these factors, we chose to study M-sec, a protein induced by IL-1b but not by VEGF-A stimulation. Our work suggests that endothelial M-sec is involved in effector lymphocyte TEM by mediating the preferential secretion of endothelial-produced inflammatory chemokines into the basolateral aspects of inflamed ECs.
The silencing of endothelial M-sec reduced lymphocyte TEM across IL-1b-stimulated EC barriers without affecting earlier steps of TEM, such as T cell arrest, crawling, and protrusion. The complete rescue of these inhibitory effects by the introduction of exogenous chemokine further suggests that the observed inhibition of lymphocyte TEM originates from abnormal encounter of endothelial-stored chemokines by adherent lymphocytes. Importantly, although M-sec silencing did not affect the production, the intracellular distribution, and the overall secretion of endothelial CCL2, it reduced the preferential secretion of CCL2 to the basolateral compartment. Therefore, our findings predict a novel link between polarized secretion of an endothelial-produced chemokine into the basolateral compartment of an EC barrier and the ability of T cells to migrate toward this compartment and complete their crossing through that endothelial barrier.
Ectopically expressed M-sec was shown to promote membrane nanotube formation in HeLa cells by interacting with the RalA and the exocyst complex [36, 37] . Nanotubes are thin membranous structures that mediate cell-cell communications over m-range distances (up to 100 mm) [38, 39] . Although subsets of ECs were also reported to produce nanotubes [40] , we did not observe these structures in resting or IL-1b-stimulated HDMVECs before or during T cell TEM, neither by light nor EM imaging. Therefore, it is unlikely that the novel functions of endothelial M-sec, identified by us, involve nanotube formation.
To our knowledge, this is the first demonstration of polarized chemokine secretion in ECs. In addition, we show that inflamed ECs secrete multiple chemokines and inflammatory cytokines, preferentially into their basolateral aspects. Importantly, the polarized secretion of all tested chemokines and cytokines that showed this pattern of distribution was affected by M-sec silencing, indicating the contribution of M-sec to this unique process. Currently, we cannot predict how general polarized cytokine secretion by inflamed ECs is, as at least 1 inflammatory chemokine (CCL20) was evenly secreted to the basolateral and apical endothelial compartments. Furthermore, as the effects of M-sec silencing on polarized cytokine secretion were incomplete, we postulate that polarized cargo secretion in inflamed HDMVECs and possibly other ECs is regulated by M-secdependent and independent mechanisms. Endothelial-produced chemotactic chemokines tightly regulate the TEM of multiple types of leukocytes [3, 6, 35] . Different mechanisms have been postulated to generate chemokine gradients over endothelial berries that direct leukocyte TEM. Blood flow is a general sink for endothelial-presented chemokines and therefore, is expected to be a principle regulator of chemokine gradient formation across vascular barriers. In addition, sharp gradients of heparan sulfate glycosaminoglycan scaffolds can help maintain steep chemokine gradients across resting and inflamed blood vessels [22] . Additional chemokinebinding moieties found in the basement membrane may also contribute to such stable chemokine gradients [41] . Therefore, it is quite interesting that in addition to these multiple mechanisms of chemokine gradient formation, inflamed ECs use a specialized inflammation-regulated factor, such as M-sec, to fine tune directional T cell TEM by optimizing the local secretion of CCL2 into their basolateral aspects to guide T cell crossing of these inflamed ECs.
Cargo secretion from regulated and constitutive vesicles, as well as polarized secretion, is controlled by the exocyst, an 8-subunit protein complex that mediates tethering of vesicles to The ratio between the chemokine or cytokine amounts secreted into the lower and upper compartments, respectively. ***P , 0.001, **P , 0.01, *P , 0.05, by Student's t test.
the plasma membrane [42, 43] . M-sec contains a sec6 domain [11] and shares sequence similarity with EXOC3, an exocyst complex component. All 8 members of the exocyst complex are constitutively transcribed in our model ECs under resting and inflammatory conditions, whereas M-sec transcription and expression are dramatically up-regulated during inflammation. Even though M-sec shares sequence similarity to exocyst components, our proteomic analysis of its interactome did not detect an interaction with this complex. Instead, M-sec was found to interact with many actin-associated proteins-some well known to control vesicular trafficking and exocytosis [28] [29] [30] [31] [32] [33] . These interactions suggest that M-sec mediates the polarized exocytosis of chemokine and cytokine vesicles via its association with the actin cytoskeletal network.
Collectively, our results are the first indication that endothelial M-sec is a novel inflammatory regulator of chemokine secretion from ECs that facilitates directional T cell migration across inflamed ECs. Future studies should further explore the mechanisms of M-sec function as a regulator of inflammatory cargo in ECs. As M-sec expression is also induced by inflammatory signals in non-ECs, including myeloid leukocytes [10, 36] , it would be interesting to explore its functions in the regulated secretion of inflammatory cargo by these cells. Cruz), Red, rabbit anti-myosin1(HPA001768; Sigma).
